Infection prevention

IRB 18724
Safety and Immunogenicity of V134 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)

VOD

IRB 16498
Phase 3 comparing Defibrotide vs SOC for VOD prevention in adults and pediatrics undergoing HSCT

IRB 20389
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

CRS

GVHD

Supportive Care

Acute GVHD

Steroid Refractory aGVHD

Intestinal aGVHD

Ocular GVHD

Chronic GVHD

Supportive Care

Key

Open for Enrollment
In Development
Enrollment on Hold

IRB 19856
EQUATE
A Study to Evaluate the Safety, Tolerability, PK, PD and Clinical Activity of EQ001 in Subjects with aGVHD

IRB 20400
BMT CTN 1802
An Open-label, Single-Arm, Multicenter Study, of Combination anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid Refractory Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

IRB 19914
GRAPHITE
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

IRB #20346
A Phase 3 Randomized, Placebo-Controlled, Double-Blinded, Multicenter, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

IRB 19856
EQUATE
A Study to Evaluate the Safety, Tolerability, PK, PD and Clinical Activity of EQ001 in Subjects with aGVHD

IRB 20400
BMT CTN 1802
An Open-label, Single-Arm, Multicenter Study, of Combination anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid Refractory Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

IRB 19914
GRAPHITE
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

IRB #20346
A Phase 3 Randomized, Placebo-Controlled, Double-Blinded, Multicenter, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)